Analysts' ratings for CME Group CME over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 4 | 2 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 4 | 3 | 1 | 0 |
| 3M Ago | 0 | 1 | 1 | 1 | 0 |
Analysts have set 12-month price targets for CME Group, revealing an average target of $276.38, a high estimate of $305.00, and a low estimate of $211.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $264.92.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive CME Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Owen Lau | Oppenheimer | Raises | Outperform | $300.00 | $282.00 |
| Alex Kramm | UBS | Raises | Buy | $305.00 | $290.00 |
| Mike Cyprys | Morgan Stanley | Raises | Overweight | $304.00 | $301.00 |
| Kyle Voigt | Keefe, Bruyette & Woods | Raises | Market Perform | $273.00 | $265.00 |
| Kenneth Worthington | JP Morgan | Lowers | Underweight | $211.00 | $223.00 |
| Benjamin Budish | Barclays | Raises | Equal-Weight | $283.00 | $279.00 |
| Owen Lau | Oppenheimer | Raises | Outperform | $279.00 | $269.00 |
| Patrick Moley | Morgan Stanley | Raises | Overweight | $301.00 | $263.00 |
| Patrick Moley | Piper Sandler | Raises | Overweight | $283.00 | $275.00 |
| Benjamin Budish | Barclays | Raises | Equal-Weight | $279.00 | $263.00 |
| Ashish Sabadra | RBC Capital | Maintains | Sector Perform | $269.00 | $269.00 |
| Craig Siegenthaler | B of A Securities | Raises | Underperform | $219.00 | $200.00 |
| Patrick O'Shaughnessy | Raymond James | Announces | Outperform | $287.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CME Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CME Group compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CME Group's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into CME Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on CME Group analyst ratings.
Delving into CME Group's Background
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
CME Group: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: CME Group's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 10.38%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: CME Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 57.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CME Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.53%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): CME Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
